Illumina Inc. (ILMN)
The price, the headline numbers and the latest news, in one place.
Illumina Inc. (ILMN) Stock Price, Analysis & Data
| Bid | 215.03 |
| Market Cap | 34.1B |
| Revenue (ttm) | 4.49B |
| Net Income (ttm) | 824M |
| 1.46 | |
| 5.35 | |
| 42.21 | |
| 37.05 | |
| P/B (ttm) | 12.02 |
| P/S (ttm) | 7.59 |
| Earnings Date | Oct 29, 2026 |
| Ask | 239.3 |
| Volume | 860,976 |
| Avg. Volume (20D) | 1,998,403 |
| Open | 220.78 |
| Previous Close | 224.99 |
| Day's Range | 220.00 - 227.67 |
| 52-Week Range | 88.00 - 227.67 |
| Analyst | Buy |
| Price Target | 211 (-6.57%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ILMN
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which s...
Financial Performance
In 2025, Illumina's revenue was 4.34B, a decrease of -0.66% compared to the previous year's 4.37B. Earnings were 850M, a decrease of -169.5%.
Financial StatementsAnalyst Forecast
According to 19 analyst ratings, the average rating for ILMN stock is "Buy". The 12-month stock price forecast is 211, which is downside of 6.57% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of n/a misses estimates by $0, with -100.00% YoY decline.
- EPS of 1.31 exceeds estimates by 0.08, with 10.08% YoY growth.
Analysts project revenue of ... Upgrade
